BioWorld

Jan. 28, 2009

CVT Rejects $1B Acquisition Offer from Partner Astellas

Astellas Pharma Inc. revealed Tuesday that it has spent the last year attempting to acquire CV Therapeutics Inc., but the biotech rejected its latest $1 billion offer and declined to engage in further discussions. (BioWorld Today) Read More

Theravance Files Telavancin NDA for Hospital-Acquired Pneumonia

Obama Election Called End of 'Sad Chapter' for Science

Mixed Bag of Pipeline News for Amgen as Earnings Fall Short

Drugmakers Slow to Personalized Medicine Risk Market Share

UK Report on Start-ups Calls for New Source of Funding

NitroMed Agrees to Deerfield Sale, but also Vows to Shop Around

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...